Hoffmann-la Roche

This study compares a new drug, NXT007, to an existing one (emicizumab) for preventing bleeding episodes in people aged 12 and older with hemophilia A. Participants may have severe, moderate, or mild disease, with or without factor VIII inhibitors. The goal is to see if NXT007 is…

This early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…

This study tests a new hormone therapy called giredestrant against a standard therapy (fulvestrant), both given with a CDK4/6 inhibitor, in people with advanced ER+/HER2- breast cancer that has stopped responding to prior hormone treatment. About 1,050 participants will be random…

This early-stage study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the disease. About…

This study is testing a new drug called glofitamab, either alone or with standard chemotherapy, in children and young adults (ages 6 months to under 30) whose mature B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. The goal is to see if the drug is saf…

This study tests whether adding a personalized cancer vaccine (autogene cevumeran) to the immunotherapy drug nivolumab works better than nivolumab alone to prevent cancer from coming back after surgery in people with high-risk bladder cancer. About 62 participants will receive ei…

This study tests an experimental drug called trontinemab in 800 people with early Alzheimer's (mild memory loss to mild dementia). The goal is to see if it can slow down worsening of thinking and daily living skills over 72 weeks. Participants receive either the drug or a placebo…

This study tests a drug called satralizumab in 120 people with two rare autoimmune brain diseases (NMDAR and LGI1 encephalitis). The goal is to see if it can improve disability and reduce the need for rescue treatments. Participants receive either the drug or a placebo, and the s…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for people with multiple myeloma who have already tried 1 to 3 prior therapies. About 380 adults will take part. The goal…

This study follows 800 adults in China who had surgery for early-stage ALK-positive non-small-cell lung cancer and then took alectinib to prevent the cancer from coming back. Researchers will track how long patients stay cancer-free in real-world settings. The goal is to see how …

This study tests an experimental drug called prasinezumab in 900 people with early-stage Parkinson's disease who are already taking levodopa. The goal is to see if the drug can delay worsening of movement symptoms compared to a placebo. Participants receive the drug or placebo by…

This study looks at the long-term safety of the drug astegolimab in people with chronic obstructive pulmonary disease (COPD). It includes about 2,000 participants who already completed a one-year study with the drug. The main goal is to track any side effects that may occur with …

This study is for people with a type of advanced breast cancer that has a specific gene change (PIK3CA) and has stopped responding to hormone therapy. It will track how well the drug inavolisib works and what side effects occur in about 500 participants in China. The goal is to s…

This study tests a new drug called glofitamab against standard treatments for people with mantle cell lymphoma that has come back or not responded to prior therapy. About 182 participants will be randomly assigned to receive glofitamab alone or one of two standard drug combinatio…

This study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …

This study looks at how well and how safe a drug called glofitamab works for Chinese adults whose large B-cell lymphoma has come back or not responded to one prior treatment. About 300 participants will receive glofitamab-based therapy and be followed to see how long they live wi…

This study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. The goal is to see if the drug can safely help children reach and stay in remission (no active sympt…

This study tests whether adding the drug inavolisib to standard maintenance therapy (Phesgo) can help people with a specific type of advanced breast cancer (HER2-positive with a PIK3CA mutation) live longer without their cancer getting worse. About 230 adults whose cancer has not…

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a certain type of advanced breast cancer (HR+/HER2- with a PIK3CA mutation) live longer without their cancer growing. About 450 adults whose cancer is hormo…

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This early-stage study is for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. It tests a drug called mosunetuzumab, either alone or combined with venetoclax, to see if it is safe and can help shrink the cancer. About 137 adult…

This early-stage study is testing whether combining two experimental drugs (mosunetuzumab or glofitamab with CC-220 and/or CC-99282) can safely treat adults with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. About 121 participants will receiv…

This study tests a new once-weekly injection called enicepatide for weight loss in 1600 adults who have obesity or overweight and type 2 diabetes. The drug works by mimicking natural hormones to help control appetite and blood sugar. Participants will receive either the drug or a…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This early-stage study tests a new drug, RO7673396, in people with advanced solid tumors that have RAS mutations. The goal is to find a safe dose and see if the drug can shrink tumors when used alone or with other cancer treatments. About 405 adults with incurable cancers will ta…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study is testing an experimental drug called fenebrutinib in 12 children and teenagers (ages 10 to under 18) with relapsing multiple sclerosis. The goal is to see how the drug works in the body, whether it reduces brain lesions seen on MRI scans, and if it is safe. Participa…

This study tests a new drug called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation in the colon. About 350 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to se…

This study tests several new drug combinations in people with advanced ER-positive breast cancer that has stopped responding to standard treatments. It includes three groups based on cancer type and prior therapy. The goal is to find which combinations are safe and effective at s…

This study tests a new gene therapy called SPK-8011QQ in 5 adult men with severe hemophilia A, a bleeding disorder. The main goal is to see if the treatment is safe and tolerable. Participants receive a single dose and are monitored for side effects.

This study tests a new drug called cevostamab in 20 Chinese patients whose multiple myeloma has come back or stopped responding to treatment. The goal is to see how the drug moves through the body, if it is safe, and whether it can shrink the cancer. Patients will receive the dru…

This early-stage study tests a new medicine called RG6496 in people who carry the gene for Huntington's disease. The goal is to check if the drug is safe and how the body processes it. About 40 participants will receive a single dose injected into the spine, with some getting a p…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This study tests a new medicine, sefaxersen, for people with a kidney disease called IgA nephropathy that is getting worse despite standard care. About 428 adults will receive either the drug or a placebo to see if it can reduce protein in the urine and protect kidney function ov…

This study is testing a drug called alectinib in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to prior treatments or have no standard options. The goal is to see if the drug is safe, how the body processes it, an…

This study tests a drug called satralizumab in children aged 2-11 with a rare disease called NMOSD that attacks the nerves. The goal is to see how the drug works in the body and if it can prevent relapses. Only 8 children will take part, and they will receive the drug regularly t…

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side effects.

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration (AMD), a condition that can cause vision loss. About 1,000 people who have already used the implant in earlier studies will…

This study tests a small implant placed in the eye that releases medicine every 24 weeks, compared to standard monthly eye injections. It includes 68 Chinese adults with wet age-related macular degeneration who have already responded to prior treatment. The goal is to see if the …

This study tests whether adding risdiplam early after gene therapy helps infants with spinal muscular atrophy (SMA) improve their motor skills. About 28 children under 2 years old with two SMN2 gene copies will receive risdiplam and be followed for 72 weeks. The main goal is to s…

This study tests a refillable eye implant that delivers medication every 36 weeks (about twice a year) for people with wet age-related macular degeneration (AMD). The goal is to see if this less frequent treatment schedule keeps vision stable and is safe. About 250 participants w…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This study looks at how well the flu drug baloxavir marboxil works in children under 12 and whether it stops the flu from spreading to family members. About 1,100 kids with flu symptoms will take the drug, and researchers will check for drug resistance and track infections in hou…

This study tests a new medicine called NXT007 to see if it works better than standard factor VIII treatment at preventing bleeds in people with hemophilia A who do not have inhibitors. About 126 people aged 12 and older will take part. The goal is to reduce the number of bleeding…

This study is testing the drug risdiplam in newborn babies with spinal muscular atrophy (SMA), a serious muscle-weakening disease. The goal is to see how the drug moves through the body and if it is safe for infants under 20 days old. Ten babies will take part, and researchers wi…

This study checks if a new version of the multiple sclerosis (MS) drug ocrelizumab works as well as the current version. About 182 adults with relapsing or primary progressive MS will get one dose of either version. The goal is to see if the drug levels in the blood are similar, …

This study is for people with metastatic colorectal cancer that has spread. Researchers are testing several targeted therapies and immunotherapies, alone or in combination, to see if they are safe and work better when matched to specific genetic markers in a patient's tumor. Abou…

This study tests several different drug combinations in people with metastatic or inoperable locally advanced breast cancer. It includes different groups based on breast cancer type and prior treatments. The goal is to see which combinations work best to control the disease and s…

This study tests whether a combination of two drugs (inavolisib plus enzalutamide) works better than standard treatments for men with a certain type of advanced prostate cancer that no longer responds to hormone therapy. About 100 participants will be randomly assigned to receive…

This early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…

This early-stage study is testing a new drug called RO7806881 in healthy volunteers to see if it is safe and how the body processes it. About 128 healthy adults will receive either the drug or a placebo. The main goal is to check for side effects and measure drug levels in the bl…

This study is a large pre-screening program to find people who may be eligible for future Alzheimer's drug trials. It involves a blood test for a key Alzheimer's protein and a memory test. No treatment is given in this study. Up to 13,000 adults with memory concerns will take par…

This study aims to understand why some breast cancers become resistant to treatment. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in proteins and g…

This study is testing a new digital platform designed to help doctors monitor people with relapsing-remitting multiple sclerosis (MS). About 500 participants will use a smartphone app, while their doctors use a separate system to track disease changes. The goal is to see if the p…

This study looks at 100 people with early-stage HER2+ breast cancer in Serbia to see if traveling farther for treatment affects whether they stick with their therapy. Researchers will compare those who travel more versus those who don't. The goal is to understand how decentralizi…

This study follows about 842 people with multiple sclerosis who are starting a new under-the-skin (subcutaneous) version of the drug ocrelizumab. Researchers want to know how satisfied patients are with this injection method after one year, and they will also measure a nerve heal…

This early-stage study tests an experimental drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check the drug's safety and how it interacts with common statins (cholesterol medicines). Participants will take the drug or a placebo and have their…

This study will follow about 850 people with wet age-related macular degeneration or diabetic macular edema who are taking the drug faricimab. Researchers will collect information from routine doctor visits over two years to see how vision changes and what treatment schedules are…

This study is observing 700 people with lung or liver cancer who are already receiving atezolizumab injections as part of their routine care. Researchers want to learn how satisfied patients are with the injection process and how it affects their quality of life. The study does n…